A large-scale meta-analysis published recently in Annals of Oncology, has examined the effect of regular aspirin use on the relative risk of cancers originating in different parts of the gastrointestinal system over time. The study pooled data from 156,000 cases and highlighted the value of additional research into the link.
Researchers from the Unit of Cancer Epidemiology at the School of Medicine, University of Milan (Italy) examined evidence from observational studies published up to 2019. Of 113 included studies on aspirin use and the risk of cancer, 45 focused on bowel cancer, with those of the head and neck, esophagus, stomach, liver and pancreas also being included. Regular aspirin use was defined as taking 1–2 tablets per week.
To view the full article, please register now for access